BAL0891 in Patients With Advanced Solid Tumors or Relapsed or Refractory Acute Myeloid Leukemia
SillaJen, Inc.
SillaJen, Inc.
Roswell Park Cancer Institute
NeoImmuneTech
George Washington University
DualityBio Inc.
Tanabe Pharma America, Inc.
National Institutes of Health Clinical Center (CC)
Numab Therapeutics AG
Stanford University
Intensity Therapeutics, Inc.
Simcha IL-18, Inc.
Cancer Research UK
Sun Yat-Sen Memorial Hospital of Sun Yat-Sen University
Icahn School of Medicine at Mount Sinai
Myeloid Therapeutics
Multitude Therapeutics Inc.
NBE-Therapeutics AG
Shanghai Yunying Medical Technology
Kineta Inc.
Shanghai Yunying Medical Technology
Nektar Therapeutics
St. Joseph Hospital of Orange
NSABP Foundation Inc
University of California, San Francisco
MultiVir, Inc.
H. Lee Moffitt Cancer Center and Research Institute
Xoft, Inc.
Hanmi Pharmaceutical Company Limited
University College, London
Azaya Therapeutics, Inc.
Cytori Therapeutics
Hadassah Medical Organization
European Institute of Oncology